Gallium-68 DOTATOC

Drug Profile

Gallium-68 DOTATOC

Alternative Names: 68Ga-DOTA(0)-phe(1)-tyr(3)-octreotide; 68Ga-DOTA-tyr3-Octreotide; 68Ga-DOTATOC; SomaKit-TOC

Latest Information Update: 31 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Unknown
  • Developer Advanced Accelerator Applications; Icahn School of Medicine at Mount Sinai; Turku University Hospital; University of Iowa
  • Class Organometallic compounds; Radioisotopes; Radiopharmaceutical diagnostics; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters; Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuroendocrine tumours
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Neuroendocrine tumours
  • Phase II/III Glioma

Most Recent Events

  • 27 Nov 2017 Central Hospital, France plans a pilot study to diagnose inflammatory phases of Myocarditis (NCT03347760)
  • 31 Mar 2017 NCM USA completes a phase III trial in Neuroendocrine tumours in USA (NCT03136328)
  • 29 Mar 2017 Advanced Accelerator Application has patent protection for Gallium-68 DOTATOC
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top